Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Immunogen Inc (IMGN)

Immunogen Inc (IMGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,315,425
  • Shares Outstanding, K 266,264
  • Annual Sales, $ 108,780 K
  • Annual Income, $ -222,930 K
  • 60-Month Beta 1.18
  • Price/Sales 28.51
  • Price/Cash Flow N/A
  • Price/Book 14.81
Trade IMGN with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.31
  • Most Recent Earnings $0.10 on 11/02/23
  • Next Earnings Date 03/06/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate 0.13
  • Number of Estimates 10
  • High Estimate 0.22
  • Low Estimate 0.07
  • Prior Year -0.23
  • Growth Rate Est. (year over year) +156.52%

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.15 +7.14%
on 01/31/24
31.25 -0.06%
on 02/09/24
+1.34 (+4.48%)
since 01/09/24
3-Month
14.26 +119.08%
on 11/13/23
31.25 -0.06%
on 02/09/24
+16.49 (+111.87%)
since 11/09/23
52-Week
3.61 +766.30%
on 03/23/23
31.25 -0.06%
on 02/09/24
+27.02 (+641.81%)
since 02/09/23

Most Recent Stories

More News
Is AbbVie Stock a Buy Now?

The company is grappling with losing Humira's patent protection in 2023.

IMGN : 31.23 (unch)
CERE : 42.90 (+0.47%)
ABBV : 172.32 (+0.69%)
AbbVie's Recent ImmunoGen Acquisition Looks Brilliant: Here's Why

The acquisition fills an immediate need with some extras to boot.

ABBV : 172.32 (+0.69%)
IMGN : 31.23 (unch)
AbbVie Just Followed Pfizer's Big Move. Here's What It Means For Investors

It's making a major acquisition to beef up a key area of its pipeline.

PFE : 29.97 (+0.88%)
ABBV : 172.32 (+0.69%)
IMGN : 31.23 (unch)
AbbVie Just Announced 2 Big Acquisitions: Is This Dividend King a No-Brainer Buy Right Now?

The big drugmaker went on a holiday shopping spree.

AGN.AX : 0.835 (-2.91%)
ABBV : 172.32 (+0.69%)
IMGN : 31.23 (unch)
CERE : 42.90 (+0.47%)
AbbVie's on an Acquisition Binge. Could Your Favorite Biotech Stock Be Next?

Here's what's attracting lucrative buyout offers from big pharmaceutical companies these days.

ABBV : 172.32 (+0.69%)
CERE : 42.90 (+0.47%)
IMGN : 31.23 (unch)
Is AbbVie Stock a Buy Now?

AbbVie's business could soon become more diversified.

AGN.AX : 0.835 (-2.91%)
ABBV : 172.32 (+0.69%)
IMGN : 31.23 (unch)
Why Abbvie Stock Popped Today

The company announces a major deal worth over $10 billion.

ABBV : 172.32 (+0.69%)
IMGN : 31.23 (unch)
Drugmaker AbbVie to spend over $10B on ImmunoGen to juice its cancer-fighting treatment portfolio

AbbVie is spending more than $10 billion to add a potential blockbuster cancer treatment as cheaper versions of the drugmaker’s all-time best seller, Humira, cut into sales

$SPX : 5,505.00 (-0.71%)
$DOWI : 40,287.53 (-0.93%)
$IUXX : 19,522.62 (-0.93%)
IMGN : 31.23 (unch)
ABBV : 172.32 (+0.69%)
ImmunoGen: Q3 Earnings Snapshot

ImmunoGen: Q3 Earnings Snapshot

IMGN : 31.23 (unch)
Pioneering the Path to Cure Cancer: 2023's Biotech Innovations

VANCOUVER – Earlier this year, the US White House requested over $2.8 billion in funding from Congress for their “Cancer Moonshot” initiative, an ambitious plan to slash cancer rates in half within...

RY : 111.13 (-0.85%)
RY.TO : 152.64 (-0.72%)
ONCY : 1.0300 (unch)
ONC.TO : 1.41 (+0.71%)
LLY : 857.47 (+1.01%)
IMGN : 31.23 (unch)
AZN : 78.71 (+0.83%)
MRK : 125.77 (+1.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

ImmunoGen Inc is a development-stage biotechnology company focused on the development of targeted cancer therapeutics using its proprietary antibody-drug conjugate technology. ImmunoGen's ADC technology is used in three development-stage candidates in its own pipeline, Roche's marketed product, Kadcyla...

See More

Key Turning Points

3rd Resistance Point 31.28
2nd Resistance Point 31.26
1st Resistance Point 31.25
Last Price 31.23
1st Support Level 31.22
2nd Support Level 31.20
3rd Support Level 31.19

See More

52-Week High 31.25
Last Price 31.23
Fibonacci 61.8% 20.69
Fibonacci 50% 17.43
Fibonacci 38.2% 14.17
52-Week Low 3.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar